U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07438847) titled '177Lu-CTR-FAPI for the Treatment of Thyroid Cancer' on Jan. 26.
Brief Summary: This is a multi-center, open-label, single-arm, dose-escalation phase I study, aiming to evaluate the safety and efficacy of 177Lu-CTR-FAPI (covalent targeted radioligand-fibroblast activation protein inhibitor), a novel radiopharmaceutical in the treatment of thyroid cancer. The primary endpoint of the study is the safety of 177Lu-CTR-FAPI, and the secondary endpoints include treatment response and dosimetry evaluation.
Study Start Date: Jan. 01
Study Type: INTERVENTIONAL
Condition:
Thyroid Cancer
Intervention:
DRUG: 177Lu-CTR-FAPI therapy
177Lu-C...